<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Polaryx Therapeutics, Inc. Common Stock — News on 6ix</title>
    <link>https://6ix.com/company/polaryx-therapeutics-inc-common-stock</link>
    <description>Latest news and press releases for Polaryx Therapeutics, Inc. Common Stock on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Tue, 21 Apr 2026 12:30:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/polaryx-therapeutics-inc-common-stock" rel="self" type="application/rss+xml" />
    <item>
      <title>Polaryx Therapeutics Receives U.S. FDA Fast Track Designations for All Four Indications to be Evaluated in the SOTERIA Basket Trial</title>
      <link>https://6ix.com/company/polaryx-therapeutics-inc-common-stock/news/polaryx-therapeutics-receives-us-fda-fast-track-designations-for-all-four-indications-to-be-evaluated-in-the-soteria-basket-trial</link>
      <guid isPermaLink="true">https://6ix.com/company/polaryx-therapeutics-inc-common-stock/news/polaryx-therapeutics-receives-us-fda-fast-track-designations-for-all-four-indications-to-be-evaluated-in-the-soteria-basket-trial</guid>
      <pubDate>Tue, 21 Apr 2026 12:30:00 GMT</pubDate>
      <description>PARAMUS, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company developing disease-modifying therapies for rare pediatric LSDs, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to PLX-200 for the treatment of Juvenile Neuronal Ceroid Lipofuscinosis (JNCL/CLN3 disease), Krabbe disease (globoid cell leukodystrophy), and Sandhoff disease (GM2 gangliosidosis Type II). Followin</description>
    </item>
    <item>
      <title>Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric Care</title>
      <link>https://6ix.com/company/polaryx-therapeutics-inc-common-stock/news/polaryx-therapeutics-recognized-with-pinnacle-award-for-excellence-in-pediatric-care</link>
      <guid isPermaLink="true">https://6ix.com/company/polaryx-therapeutics-inc-common-stock/news/polaryx-therapeutics-recognized-with-pinnacle-award-for-excellence-in-pediatric-care</guid>
      <pubDate>Wed, 15 Apr 2026 13:15:00 GMT</pubDate>
      <description>Company selected as a Diamond honoree for Excellence in Pediatric CarePARAMUS, NJ, April 15, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (Nasdaq: PLYX), a clinical-stage biotechnology company focused on developing disease-modifying therapies for rare, pediatric lysosomal storage disorders (LSDs), announces that it has been named a winner of the 2026 Pinnacle Awards for Healthcare, being selected as a Diamond honoree for Excellence in Pediatric Care. Polaryx was recognized for its innovative an</description>
    </item>
    <item>
      <title>Polaryx Therapeutics To Participate In The 25th Annual Needham Virtual Healthcare Conference</title>
      <link>https://6ix.com/company/polaryx-therapeutics-inc-common-stock/news/polaryx-therapeutics-to-participate-in-the-25th-annual-needham-virtual-healthcare-conference-7</link>
      <guid isPermaLink="true">https://6ix.com/company/polaryx-therapeutics-inc-common-stock/news/polaryx-therapeutics-to-participate-in-the-25th-annual-needham-virtual-healthcare-conference-7</guid>
      <pubDate>Wed, 01 Apr 2026 04:00:00 GMT</pubDate>
      <description>PARAMUS, NJ, April 01, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel,</description>
    </item>
    <item>
      <title>Polaryx Therapeutics Receives FDA Fast Track Designation for PLX‑200 for Late‑Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease)</title>
      <link>https://6ix.com/company/polaryx-therapeutics-inc-common-stock/news/polaryx-therapeutics-receives-fda-fast-track-designation-for-plx200-for-lateinfantile-neuronal-ceroid-lipofuscinosis-cln2-disease</link>
      <guid isPermaLink="true">https://6ix.com/company/polaryx-therapeutics-inc-common-stock/news/polaryx-therapeutics-receives-fda-fast-track-designation-for-plx200-for-lateinfantile-neuronal-ceroid-lipofuscinosis-cln2-disease</guid>
      <pubDate>Tue, 17 Mar 2026 04:00:00 GMT</pubDate>
      <description>Regulatory milestone supports advancement of the SOTERIA Phase 2 basket trial evaluating PLX‑200 across multiple lysosomal storage disorders PARAMUS, NJ,</description>
    </item>
    <item>
      <title>Polaryx Therapeutics Deepens Engagement with the Krabbe Disease Community Through Scientific and Patient Advocacy Events</title>
      <link>https://6ix.com/company/polaryx-therapeutics-inc-common-stock/news/polaryx-therapeutics-deepens-engagement-with-the-krabbe-disease-community-through-scientific-and-patient-advocacy-events-6</link>
      <guid isPermaLink="true">https://6ix.com/company/polaryx-therapeutics-inc-common-stock/news/polaryx-therapeutics-deepens-engagement-with-the-krabbe-disease-community-through-scientific-and-patient-advocacy-events-6</guid>
      <pubDate>Thu, 12 Mar 2026 04:00:00 GMT</pubDate>
      <description>PARAMUS, NJ, March 12, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel,</description>
    </item>
    <item>
      <title>Polaryx Therapeutics Marks Rare Disease Day, Reaffirming Commitment to Patients with Rare Pediatric Lysosomal Storage Disorders</title>
      <link>https://6ix.com/company/polaryx-therapeutics-inc-common-stock/news/polaryx-therapeutics-marks-rare-disease-day-reaffirming-commitment-to-patients-with-rare-pediatric-lysosomal-storage-disorders</link>
      <guid isPermaLink="true">https://6ix.com/company/polaryx-therapeutics-inc-common-stock/news/polaryx-therapeutics-marks-rare-disease-day-reaffirming-commitment-to-patients-with-rare-pediatric-lysosomal-storage-disorders</guid>
      <pubDate>Fri, 27 Feb 2026 05:00:00 GMT</pubDate>
      <description>PARAMUS, NJ, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying</description>
    </item>
    <item>
      <title>Polaryx Therapeutics Selects Contract Research Organization for SOTERIA Phase 2 Basket Trial</title>
      <link>https://6ix.com/company/polaryx-therapeutics-inc-common-stock/news/polaryx-therapeutics-selects-contract-research-organization-for-soteria-phase-2-basket-trial</link>
      <guid isPermaLink="true">https://6ix.com/company/polaryx-therapeutics-inc-common-stock/news/polaryx-therapeutics-selects-contract-research-organization-for-soteria-phase-2-basket-trial</guid>
      <pubDate>Tue, 17 Feb 2026 05:00:00 GMT</pubDate>
      <description>PARAMUS, NJ, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel,</description>
    </item>
    <item>
      <title>Polaryx Announces Key Pre-Clinical Data Related to SOTERIA at the 22nd Annual WORLDSymposium™</title>
      <link>https://6ix.com/company/polaryx-therapeutics-inc-common-stock/news/polaryx-announces-key-pre-clinical-data-related-to-soteria-at-the-22nd-annual-worldsymposiumtm</link>
      <guid isPermaLink="true">https://6ix.com/company/polaryx-therapeutics-inc-common-stock/news/polaryx-announces-key-pre-clinical-data-related-to-soteria-at-the-22nd-annual-worldsymposiumtm</guid>
      <pubDate>Tue, 10 Feb 2026 05:00:00 GMT</pubDate>
      <description>Oral presentation highlighted the effect of gemfibrozil on Krabbe disease, one of four LSDs in the upcoming Phase 2 SOTERIA basket trial evaluating PLX-200</description>
    </item>
    <item>
      <title>Polaryx Therapeutics Welcomes New Members of the Board of Directors</title>
      <link>https://6ix.com/company/polaryx-therapeutics-inc-common-stock/news/polaryx-therapeutics-welcomes-new-members-of-the-board-of-directors</link>
      <guid isPermaLink="true">https://6ix.com/company/polaryx-therapeutics-inc-common-stock/news/polaryx-therapeutics-welcomes-new-members-of-the-board-of-directors</guid>
      <pubDate>Thu, 05 Feb 2026 05:00:00 GMT</pubDate>
      <description>PARAMUS, NJ, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX) a clinical-stage biotechnology company dedicated to the discovery,</description>
    </item>
    <item>
      <title>Polaryx to Present Late-Breaker Data Related to SOTERIA at the 22nd Annual WORLDSymposium™ as Company Prepares for SOTERIA Trial Launch</title>
      <link>https://6ix.com/company/polaryx-therapeutics-inc-common-stock/news/polaryx-to-present-late-breaker-data-related-to-soteria-at-the-22nd-annual-worldsymposiumtm-as-company-prepares-for-soteria-trial-launch</link>
      <guid isPermaLink="true">https://6ix.com/company/polaryx-therapeutics-inc-common-stock/news/polaryx-to-present-late-breaker-data-related-to-soteria-at-the-22nd-annual-worldsymposiumtm-as-company-prepares-for-soteria-trial-launch</guid>
      <pubDate>Tue, 03 Feb 2026 05:00:00 GMT</pubDate>
      <description>Oral presentation provides additional scientific rationale on Krabbe disease, one of four LSDs in the Phase 2 SOTERIA basket trial designed to evaluate the</description>
    </item>
    <item>
      <title>Polaryx Therapeutics Announces Direct Listing on Nasdaq; Shares to Begin Trading Under the Symbol “PLYX”</title>
      <link>https://6ix.com/company/polaryx-therapeutics-inc-common-stock/news/polaryx-therapeutics-announces-direct-listing-on-nasdaq-shares-to-begin-trading-under-the-symbol-plyx</link>
      <guid isPermaLink="true">https://6ix.com/company/polaryx-therapeutics-inc-common-stock/news/polaryx-therapeutics-announces-direct-listing-on-nasdaq-shares-to-begin-trading-under-the-symbol-plyx</guid>
      <pubDate>Mon, 02 Feb 2026 05:00:00 GMT</pubDate>
      <description>PARAMUS, NJ, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (“Polaryx” or the “Company”) a clinical-stage biotechnology company dedicated to the</description>
    </item>
    <item>
      <title>Polaryx Therapeutics Announces Approval to List Common Stock on Nasdaq</title>
      <link>https://6ix.com/company/polaryx-therapeutics-inc-common-stock/news/polaryx-therapeutics-announces-approval-to-list-common-stock-on-nasdaq</link>
      <guid isPermaLink="true">https://6ix.com/company/polaryx-therapeutics-inc-common-stock/news/polaryx-therapeutics-announces-approval-to-list-common-stock-on-nasdaq</guid>
      <pubDate>Fri, 30 Jan 2026 13:00:00 GMT</pubDate>
      <description>PARAMUS, NJ, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (“Polaryx” or the “Company”) a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”), today announced that shares of the Company’s common stock have been approved for listing on the Nasdaq Capital Market (“Nasdaq”) under the ticker symbol “PLYX”. Shares of Polaryx common stock are expected</description>
    </item>
  </channel>
</rss>